** Shares of ophthalmic medical device company Rxsight RXST.O fall 23.8% to $19.9 premarket
** Co late on Wednesday lowered its annual revenue forecast to range between $160.0 million and $175.0 million from a previous range of $185 million to $197 million
** RXST expects preliminary Q1 revenue of $37.9 million, lower than analysts' average estimate of $39.59 million as per data compiled by LSEG
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and their median PT is $43 - LSEG data
** Up to last close, RXST stock has fallen 93% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。